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INTRODUCTION  
Methotrexate (MTX), an antimetabolite 
drug  is being used since decades for a vast 
number of conditions. The mechanism of 
action points towards inhibition of 
dihydrofolic acid reductase and directing 
towards the synthesis of folic acid which 
is mandatory for DNA synthesis and 
repair. MTX, in lower doses, reduces cell 
proliferation and inhibits proliferation of 
lymphocytes and cytokine synthesis.1 It 
works by inducing programmed cell 
death (apoptosis) and increasing the 
concentration of adenosine. It  is  also  a  
component  of  chemotherapy regimens 
against breast and lung cancer, 
lymphomas or squamous cell cancer.1,2 
MTX can induce  mild to severe side 
effects ranging from gastrointestinal 
symptoms to multi organ failure. 
Gastrointestinal  toxicity, nausea, 
diarrhea, vomiting,  mouth and lip sores,   
 
 
stomatitis, balanitis, anorexia, 
pharyngitis, enteritis, pneumonitis, 
hepatitis, pruritus,  urticaria,  ecchymosis, 
alopecia, ulcerations  of  psoriatic  
plaques,  erosions  of  the  mucosa  and 
toxic epidermal necrolysis.2,3,4 Subjects 
with methotrexate toxicity are more 
prone to infections and fever due to 
immunosuppression. Mucosal cells are 
more prone to get affected because of 
their highly replicative nature. Reports 
suggest that withdrawal of the drug show 
a positive dechallenge phenomena 
leading to complete resolution within a 
few days.4  MTX can be administered via 
many routes. In human plasma, over 50% 
of MTX is bound to albumin2,3 and any 
medication with a high plasma protein 
affinity can easily displace it. MTX is 
excreted via kidneys, with only a  minor  
portion  is  metabolized  in  the  liver.2 
Consequently, renal impairment and low 
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GFR may lead to accumulation, to higher 
blood levels and to toxicity.3  As the 
cutaneous erosions tend to heal quickly 
within few weeks of stopping or 
decreasing the dose of methotrexate, the 
treatment required for these symptoms is 
mainly supportive.5,6 Management with 
intravenous hydration, urine 
alkalinization, and high dose leucovorin 
are effective in the management of acute 
toxicity.7 Leucovorin helps to replenishes 
the intracellular levels of reduced folate 
bypassing the dihydrofolic acid reductase 
and provides substrates needed for purine 
and thymidylate synthesis.2 MTX toxicity 
can be fatal 0r life-threatening if not 
followed by adequate treatment 
strategies. So, it is recommended to 
initiate the rescue measures 
independently of drug blood levels if the 
patient shows evidence of toxicity related 
clinical symptoms. 
  
CASE PRESENTATION 
A 35-year-old  man  presented  to our 
clinic with stomatitis and multiform 
exanthema. Ten months before the 
current presentation, the patient had 
noticed small red round patches covered 
by shiny scales on right elbow and wrist. 
During the following months, the lesions 
progressed and spread to the all the 
extremities and also involving the trunk 
to some extent. In  October  2016,  the  
patient  visited  his  family doctor  due  to  
the  progressive  changes.  The doctor 
suspected psoriasis vulgaris and started 
treatment with topical corticostroids and 
MTX at an dosage of 5 mg once a day for 
a week followed by 10 mg daily. A week 
later, the patient developed flu-like 
symptoms, throat pain, productive cough 
and difficulty in eating. His lips were 
fissured painfully swollen. His left foot 
showed erythema and swelling. The 
symptoms worsened gradually, involving 
different skin areas until presentation to 
us 2 weeks after initiation of MTX 
therapy. On admission, the patient had 
fever, night sweats and massive pain in all 
affected areas, On examination, the 
patient was febrile (body temperature 
38.4c) and in reduced overall general 
condition. Dermatological examination 
revealed multiple, ulcerated, 
erythematous plaques of 1–3 cm in 
diameter, distributed predominantly on 
all the extremities, with fewer lesions on 
the trunk. The ulcerations were 
surrounded by edematous areas. Erosive 
lesions were detected in the oral cavity. 
Swelling in the submandibular lymph 
nodes was evident, but other lymph nodes 
were unremarkable. 
 
He was a non-alcoholic and a past 
smoker. His regular medication prior to 
admission was metformin for diabetes 
and MTX  (10  mg  daily).Once weekly, he 
took chewable Vitamin C. Based on the 
characteristic history and clinical 
presentation, we interpreted the clinical 
picture as a consequence of the excessive 
MTX intake. Due to the severe skin 
involvement, MTX was discontinued 
immediately.Laboratory investigations on 
admission showed elevated CRP. 
Haematological examination showed 
decrease in number of red blood cells, 
white blood cells and platelets pointing 
towards pancytopenia that might have 
been resulted because of the drug induced 
myelosuppression. Other laboratory 
findings including skin swab test and 
serological tests were unremarkable. The 
patient was put on broad spectrum 
antibiotics. 
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A histopathology of the representative 
skin lesion revealed hyperkeratosis, 
vacuolar alteration, apoptotic 
keratinocytes in the stratum basale of the 
epidermis. Moreover, it showed scanty 
lymphocytic peri-vascular infiltrates in 
the upper dermis with neutrophils and 
discrete intradermal erythrocyte 
extravasation. There were signs of 
lichenoid dermatitis and interface 
dermatitis. Topical therapy with 
triamcinolone and halometasone was 
started for cutaneous lesions and for 
mucosal lesions anesthetic gel was used 
along with triamcinolone tincture. 
Antiseptic baths (potassium 
permanganate) and analgesics were 
prescribed. No potential focus of infection 
was revealed in blood cultures, urine 
cultures and thoracic radiographic 
imaging. An antidote therapy with folinic 
acid was administered for 2 days. 
Adequate hydration and urinary 
alkalinization with sodium bicarbonate 
was done to increase MTX excretion. The 
patient healed gradually with regression 
of all lesions within few days after starting 
local and systemic therapy.  After 11 days 
of treatment, the blood cell count 
reverted to normal with cessation of all 
the symptoms. The patient was dismissed 
in good general condition.  During 
subsequent follow-ups, no drug toxicity 
related symptoms were detected. 
 
DISCUSSION 
We describe the clinical picture and 
management of a case of acute MTX 
toxicity. The most common causes 
leading to MTX intoxication are 
inappropriate dosage, impairment of  
renal  function  and  thus  decreased  
excretion,  concomitant  use  of  
interacting drugs.4 Methotrexate, a folic 
acid antagonist that inhibits DNA and 
RNA synthesis by binding to the enzyme 
dihydrofolate reductase ,is widely used in 
the treatment of proliferative disorders.8 
Methotrexate toxicity manifests itself in 
several forms including liver toxicity, lung 
toxicity, renal failure, gastrointestinal 
tract symptoms, and pancytopenia.8,9 It 
can also cause more rare cutaneous side 
effects including burning sensation of the 
skin, sloughing over pressure points, 
severe mucositis, and Stevens-Johnson 
syndrome.5,10,11 The histolpathological 
findings in the biopsy were in line with 
those of patients suffering from MTX 
intoxication. The histopathological study 
of eroded cutaneous lesions shows a 
microscopic image similar to that 
observed after intradermal 
administration of the drug, suggesting 
that the reaction is caused by a direct 
cytotoxic effect.12 In case of acute MTX 
intoxication, cutaneous signs and 
symptoms may precede other serious 
adverse events as a warning sign. The 
treatment is made with immediate 
suspension of the drug and 
administration of folinic acid. In a review 
of the literature from 1951 to 1996, Pearce 
and Wilson13 found 64 patients, who had 
experienced cutaneous erosions believed 
to be secondary to methotrexate toxicity. 
Drug interaction has also been counted as 
one of the potent causes of methotrexate 
induced toxicity. Daly et al14 reported case 
of methotrexate toxicity which occurred 
due to co-administration of 
azapropazone. Ng et al15 described a 
patient who developed necrotic skin 
ulceration and pancytopenia after 
concomitant administration of 
methotrexate, trimethoprim, and 
naproxen. Mucocutaneous  ulceration  on  
psoriatic  plaques  or previously healthy 
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skin due to MTX administration may 
indicate the  development  of  other  
severe  organ  damage  such  as  bone  
marrow  suppression and multiorgan 
failure. However, perhaps due to the 
timely diagnosis and initiation of rescue 
therapy, our patient experienced a quick 
and complete recovery. He developed 
ulcerated livid plaques on previously 
healthy skin and ulceration of pre-
existing psoriatic plaques, oral mucositis. 
The skin  lesions  preceded  a  severe  
pancytopenia.  Under rescue therapy, 
both skin lesions and pancytopenia  
resolved  within a few  days.  Physicians 
should be aware of the existence and 
morphology of MTX-induced skin lesions 
in order to take appropriate therapeutic 
action at an early stage and prevent the 
development of further complications. 
 
CONCLUSION 
In conclusion, this case depicts the 
importance of recognizing clinical signs 
of methotrexate toxicity and initiating 
therapy as soon as possible. Methotrexate 
is an option of great therapeutic value for 
countless disorders, yet it is not clear 
whether the benefits outweigh the risks or 
not. The healthcare professionals and the 
patients need to be thoroughly aware of 
the risks and side effects of methotrexate. 
MTX, being used worldwide, is a safe and 
effective drug, but the outcome may be 
fatal depending upon inappropriate use, 
dosage, concomitant medications and 
underlying medical condition of the 
subject. Prior workup and proper 
counseling regarding the drug 
interactions as well as self-medication 
should be enforced. 
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